Galmed (GLMD) announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of ...

The American Association for the Study of Liver Diseases (AASLD) is inviting members to apply as site principal investigators to participate in TARGET-LD, which broadly studies outcomes for patients ...

FEI-Zyfer, Inc., a wholly-owned subsidiary of Frequency Electronics, Inc. ("FEI" or the "Company") , a leading provider of precision timing and frequency control products, is pleased to announce the ...

Fifteen community members braved the cold and snow the evening of March 7 to join national demonstrations to “Stand Up for ...

A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...

obesity and dyslipidemia contributes to the development of Non-alcoholic fatty liver disease (NAFLD) which can further worsen to Non-alcoholic Steatohepatitis (NASH) and ultimately liver fibrosis ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

The AI-based AIM-NASH tool employs a machine learning model trained on more than 100,000 annotations from 59 pathologists who assessed over 5,000 liver biopsies across nine large clinical trials.

The company was based in Las Vegas and touted its products’ health benefits when the water contained a toxic chemical used in ...

Real Water’s product contained a toxic chemical used in rocket fuel and was linked to a liver failure outbreak in Southern ...

NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects millions of people and which, for several years, has been billed as pharma's next big growth area. Although, so far efforts ...

Ghent, Belgium – 20 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease ...